Abiogen Pharma takes over Altamedics in a deal worth $8 million

Date: 2022-12-09   Author: Pankaj Singh  Category: #news

Abiogen Pharma takes over Altamedics in a deal worth $8 million

Italy-based pharmaceutical company Abiogen Pharma S.p.A. has reportedly completed the acquisition of Altamedics GmbH, a German pharmaceutical distribution company, which is slated to become the first foreign branch of Abiogen. The acquisition, worth nearly USD 8 billion (8 million euros), signifies completing the first step of Abiogen Pharma's internationalization plan unveiled seven years ago.

Speaking on the latest development, Massimo Di Martino, Chairman and CEO of Abiogen Pharma, mentioned that the main objective is to make Abiogen an international firm without losing the core nature of being Italian and having a family business, further adding that this is the beginning of stimulating future expansion into other countries.

Massimo added that the firm it has recently acquired in Germany is similar to Abiogen, considering the logistics and its values and principles. It is a commercial firm that currently delivers well-recognized products in the therapeutic areas that the firm targets (pain and musculoskeletal treatment), cited Massimo.

Prisca Di Martino, IBU (International Business Unit) Head, Abiogen Pharma, added that the main goal is not to change the nature of Altamedics but rather to broaden it by leveraging the firm's expertise while building a strong network of medical sales representatives eager to participate in scientific information and promotion, a service that is not available at present within this company.

Martino mentioned that Abiogen Pharma seeks to broaden its product portfolio soon and acquire businesses with the same cultural and logistical approaches. The IBU head also noted that the firm is targeting new branches in Europe.

For the unfamiliar, Cologne-based Altamedics operates in several overseas markets, focusing primarily on the distribution of pharmaceuticals in hospital settings and high-value-added and specialty products.

For the record, Abiogen Pharma is also planning to unveil and distribute products under its name, the very first in the bone metabolism section, along with supporting Altamedics' products in Germany. These are further slated to offer several benefits to Abiogen Pharma in Italy and abroad, perhaps via further distribution agreements in other countries.

Source credit - https://www.prnewswire.com/news-releases/abiogen-pharma-acquired-altamedics-301697242.html

About Author

Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Cardiac Resynchronization Therapy (CRT) Devices Market to 2026 - Growth Trends and Revenue Statistics

Author: Rahul Varpe

A highly analytical qualitative as well as quantitative evaluation of the Cardiac Resynchronization Therapy (CRT) Devices Market has been covered in this report. The study evaluates the myriad aspects of this industry by taking into consideration ...

Medical Products Market Growth Rate, Revenue and Demand Analysis to 2026

Author: Rahul Varpe

An extremely definite evaluation of the Medical Products Market in terms of qualitative as well as quantitative analysis has been covered in this report. The myriad aspects of this industry, having considered its historical and forecast data have ...

Intensive Care Beds Market - Geography Insights and Opportunity Analysis to 2026

Author: Rahul Varpe

The latest study provides an in-depth analysis of the Intensive Care Beds Market focusing on various market definitions, segmentations, sub-segmentations, products, as well as applications. The report further details of the competitive landscape &...